Table 1.

Characteristics of patients in the included studies

Author, year	Number	Cell type	Cell dose	Course of treatment (months)
Amit N Patel, 2016 [24]	66	Ixmyelocel-T+BMA	0.8 ml	12
	60	Placebo+BMA	0.8 ml	12
Amit N. Patel, 2005 [11]	10	Stem cells (CD34+)	250 ml	6
	10	Own plasma	30 ml	6
Amit N. Patel, 2015 [12]	24	BMAC infusion	240 ml	12
	6	Medical standard of care	–	12
Anders Bruun Mathiasen, 2015 [13]	40	MSCs	0.2 ml	6
	20	PBS	0.2 ml	6
Emerson C. Perin, 2011 [6]	20	ABMMNC	3 ml	6
	10	Simulated mock injection	–	6
Emerson C. Perin, 2012 [2]	10	ALDHbr	3 ml	6
	10	5% Albumin	3 ml	6
Emerson C. Perin, 2003 [7]	14	ABMMNC	50 ml	2
	7	Placebo	–	4
Jozef Bartunek, 2013 [3]	32	Bone marrow stem cells	50 × 106	24
	15	Standard of care	–	24
Shengshou Hu, 2011 [8]	31	CABG+BMMNC	60 ml	6
	29	CABG	10 ml	6
Zhi Qi, 2015 [25]	24	CABG+BMMNC	60 ml	12
	18	CABG	10 ml	12
Evgeny Pokushalov, 2010 [26]	49	ABMMNC+Medical therapy	41 ± 16 × 106	12
	31	Medical therapy	–
Nabil Dib, 2009 [27]	12	AMT+MMT	2.5 × 107	12
	11	MMT	–
Philippe Menasché, 2008 [29]	30	Myoblast	8 × 108	6
	34	Placebo	–
Qiang Zhao, 2008 [28]	18	BMMNC	An average of 6.59 × 108 ± 5.12 × 108	6
	18	Saline	–

BMA bone marrow aspirate, BMAC bone marrow aspirate concentrate, MSCs mesenchymal stromal cells, PBS phosphate buffer saline, BMC bone marrow cell, ABMMNC autologous bone marrow mononuclear cell, ALDHbr aldehyde dehydrogenase-bright, MPCs mesenchymal precursor cells, CABG coronary artery bypass graft, BMMNC bone marrow mononuclear cell, AMT autologous myoblast transplant, MMT maximal medical therapy